DDInter222 DDInter1340
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs . Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Bortezomib {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Omeprazole
Bortezomib {u} (Compound) causes {v} (Side Effect) Urethral disorder
Urethral disorder {u} (Side Effect) is caused by {v} (Compound) Omeprazole
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Bortezomib {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Bortezomib {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Lansoprazole
Lansoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Bortezomib {u} (Compound) causes {v} (Side Effect) Urethral disorder
Urethral disorder {u} (Side Effect) is caused by {v} (Compound) Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Bortezomib {u} (Compound) causes {v} (Side Effect) Fungal infection
Fungal infection {u} (Side Effect) is caused by {v} (Compound) Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pantoprazole and Pantoprazole (Compound) resembles Omeprazole (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole (Compound) resembles Omeprazole (Compound)
Bortezomib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Omeprazole (Compound)
Bortezomib (Compound) causes Urethral disorder (Side Effect) and Urethral disorder (Side Effect) is caused by Omeprazole (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pantoprazole and Pantoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole (Compound) resembles Omeprazole (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole (Compound) resembles Omeprazole (Compound)
Bortezomib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pantoprazole (Compound) and Pantoprazole (Compound) resembles Omeprazole (Compound)
Bortezomib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Lansoprazole (Compound) and Lansoprazole (Compound) resembles Omeprazole (Compound)
Bortezomib (Compound) causes Urethral disorder (Side Effect) and Urethral disorder (Side Effect) is caused by Pantoprazole (Compound) and Pantoprazole (Compound) resembles Omeprazole (Compound)
Bortezomib (Compound) causes Fungal infection (Side Effect) and Fungal infection (Side Effect) is caused by Esomeprazole (Compound) and Esomeprazole (Compound) resembles Omeprazole (Compound)